Immunology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

This Phase 2 trial is testing a new treatment called PVX108 for children and adolescents who have peanut allergies. The goal is to reduce allergic reactions to peanut protein, which could significantly improve daily safety and quality of life for young patients. The study is active but not recruiting, with participants enrolled in the United States and Australia.

Omalizumab to Accelerate a Symptom-driven Multi-food OIT

This completed Phase 2 trial explored using omalizumab along with oral immunotherapy to treat children and young adults with multiple food allergies. By potentially speeding up the time to reach maintenance treatment doses, this approach could make managing multiple allergies faster and less risky. The study involved 90 participants aged 6 to 25 in Canada.

A Longitudinal Natural History Study of Immune Biomarkers in Neuropsychiatric Illness

This study is gathering blood samples from people of all ages with brain or mental health conditions that might involve the immune system. Its goal is to find immune markers that could help doctors better diagnose and treat these complex illnesses. The study is currently recruiting participants in the United States and includes follow-up visits over several years.

Fecal Microbiota Transplantation (FMT) to Slow Biological Aging

This clinical trial is testing whether taking capsules containing beneficial bacteria from healthy donors can slow biological aging in adults aged 45 to 80. The treatment could reduce inflammation and improve both metabolic and cognitive health by positively changing the gut microbiome. Participants receive multiple doses over months and undergo regular health and cognitive assessments.

Rapid Escalation Oral Immunotherapy to Achieve Remission in Children With Cashew Allergy

This upcoming trial plans to study a fast-paced oral immunotherapy treatment aimed at helping children with cashew allergies build tolerance safely. If successful, it could offer an alternative to strict avoidance and improve children’s quality of life. The study intends to enroll 25 children but is not yet recruiting.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.